a 0.5mg dose requires 0.1mL (10 units on a 100-unit syringe)
These include improved insulin sensitivity and reduced inflammation, which contribute to better overall health
these were SUSTAIN 1, 2, 3, 6, and SUSTAIN-Japan [13,14,15, 19, 20]
Such claims lack human trial support
A meta-analysis of eight clinical trials including ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (subcutaneous injectable semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (duraglutide), PIONEER-6 (oral administrated semaglutide) and AMPLITUDE-O (efpeglenatide) showed that GLP-1RA reduced MACE by 14% (HR 0.86, 95% CI 0.800.93) [11]
Safety Adverse effects In general, high-dose lipoic acid administration has been found to have few serious side effects